Iveta Kudaba

Iveta Kudaba is an Associate Professor in the Department of Internal Diseases at Rīga Stradiņš University, Faculty of Medicine. Her academic and clinical work is centered on oncology, particularly breast cancer, lung cancer, and gastrointestinal malignancies. She actively contributes to international clinical trials and serves as a supervisor in PhD research.

Her research interests lie at the intersection of clinical oncology and translational medicine, with a strong emphasis on immunotherapy, targeted therapies, and biomarker development. She focuses on evaluating the efficacy of agents like pembrolizumab and trilaciclib in various cancers, including non-small cell lung cancer, metastatic breast cancer, and gastric cancer. Her work contributes to advancing precision medicine and improving patient outcomes.

The analysis of her recent publications reveals a consistent focus on large-scale, phase III clinical trials in oncology, particularly those sponsored by pharmaceutical companies and coordinated internationally. Her work frequently appears in high-impact journals such as the Journal of Clinical Oncology and Clinical Cancer Research. The dominant themes include immunotherapy efficacy, survival outcomes, myeloprotection, and biomarker validation across solid tumors.

Iveta Kudaba plays a significant role in academic mentorship and research supervision. She is currently supervising a PhD project titled "MicroRNA expression as a predictive biomarker for locally advanced breast cancer to evaluate the efficacy of systemic treatment." Her involvement in peer review and conference activities further underscores her engagement in the academic community.

She is actively involved in major international oncology conferences, including the American Society of Clinical Oncology (ASCO) Annual Meeting, European Society for Medical Oncology (ESMO) Breast Cancer, and the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer. These activities highlight her integration into the global oncology research network.